We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 05, 2022

Abiraterone Acetate + ADT Improves Survival in mCSPC Regardless of Visceral Disease Status

European Journal of Cancer


Additional Info

European Journal of Cancer
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study
Eur. J. Cancer 2021 Dec 22;162(xx)56-64, G Baciarello, M Özgüroğlu, S Mundle, G Leitz, U Richarz, P Hu, S Feyerabend, N Matsubara, KN Chi, K Fizazi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading